Annals of Internal Medicine has published the updated 2025 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guidelines on adult Overweight and Obesity management. Here is a review of the guidelines, including five key takeaways for rheumatologists.
Dr. John Cush RheumNow
4 hours 3 minutes ago
FDA FAERS pharmacovigilance study of MSK serious adverse reports w/ GLP-1 RAs - Muscle atrophy showed the strongest AE, w/ less freq reports of back pain, muscle spasms, neck pain. https://t.co/4xRH6yWH1o https://t.co/MKCKtkFd1u
Dr. John Cush RheumNow
5 hours 33 minutes ago
2024 death rates from unintentional falls among adults≥65 yrs were 74.8/100K for men (66.6 women) Rates were higher for men > women. Fall death rates incr w/ age: highest ≥85 years. https://t.co/b4RwFHbZKj https://t.co/8m9mGUewYu
Dr. John Cush RheumNow
8 hours 26 minutes ago
Rheum Survey: Beyond weight loss, How will GLP-1 drugs benefit rheumatic pts?
Dr. John Cush RheumNow
12 hours 33 minutes ago
Earlier Dx of axSpA is assoc w/ lower long-term spinal structural damage. Swiss study compared xray outcomes betw 138 early (<2yrs) & 238 established axSpA pts w/ 11.5 yrs F/U. Differences became evident 10-15 yrs after Dx. https://t.co/E9oR37CEiD https://t.co/7FiaqJIRRC
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
Dr. John Cush RheumNow
1 day 4 hours ago
Estimated > 7million Americans (~1/3 US GLP1 Rxs) get GLP-1 drugs from online compounding source- but these are not FDA approved. They maybe cheaper, but dosing/quality is suspect. FDA needs to close the 503B loophole to outlaw these copycat Rxs https://t.co/Xu7MeP0Ytt https://t.co/nYGr3auqzx
Dr. John Cush RheumNow
1 day 5 hours ago
Retrospective review of 33 referred pts w/ Recurrent fever w/ MSK & skin Sxs, assessed by NGS. NLRP1 had FMF-like Dz; NLRP recurrent fevers w/ mucocutaneous; NLRP12 periodic fevers w/ MP/EN rash; NLRC4 episodic systemic inflammation GI Sxs & atypical skin rash https://t.co/IWafJVFoaJ
When it rains it pours, but when it comes to grief, it’s like the rains that just won't let up.Just too many deaths this past month. All devastating, all my immediate sphere. All hard to fathom. How can something so inevitable be a recurring, unwelcome, unsolvable bad dream?I lost my father when I was 15, my sister was 20 and my mother when I was in medical school. And I've done this many, many times since.
Dr. John Cush RheumNow
1 day 7 hours ago
Southern Israel study (2009-24) shows fibromyalgia prevalence Incr from 1.04% to 3.88%, esp 30-59 yrs; more males, w/ more Psych comorbidities; fewer hospitalizations & specialist visits but increased imaging. More use of pregabalin, duloxetine, & gabapentin. https://t.co/kgmvdZF9HQ
Dr. John Cush RheumNow
1 day 9 hours ago
Systematic review of 290 psoriasis pregnancies 211 live births (73%) finds biologic exposure (UST 241, 42 TNFi) during PREG assoc w/ favorable maternal/fetal outcomes. Only 24 cont either CZP or ADA throughout PREG. Rates of miscarriage, LBW, congenital anomalies, comparable w/ https://t.co/H5GLrvxwPv
Dr. John Cush RheumNow
1 day 11 hours ago
Indian Single center retrospective study of 28 children ≤18 yrs tested w/ 18F-FDG-PET/MR for pyrexia (PUO). 25% Dx w/ pre-stenotic TAKayasu (mean 13.9 yrs), & 20/21 alternative Dxs. All had Sxs & high ESR/CRP; all Rx w/ GC & MMF, 3 w/ biologics https://t.co/6trs1WssjW https://t.co/EOPIarRhY5
Dr. John Cush RheumNow
1 day 12 hours ago
It’s almost time. 🔥
Registration for RheumNow Live 2027 opens OCTOBER 1.
Two days of practical, engaging rheumatology education designed to challenge how you think and influence how you practice.
📅 Jan 30–31, 2027
📍 Dallas + Online https://t.co/Ju0zzYX8Tl
Dr. John Cush RheumNow
1 day 12 hours ago
Prescribing New GLP-1-Based Therapies
https://t.co/cpxyxBMZ8s https://t.co/9JXmlW2Lj6
